JP4200593B2 - Crystalline L-ascorbic acid-2-phosphate sodium salt and process for producing the same - Google Patents
Crystalline L-ascorbic acid-2-phosphate sodium salt and process for producing the same Download PDFInfo
- Publication number
- JP4200593B2 JP4200593B2 JP17566599A JP17566599A JP4200593B2 JP 4200593 B2 JP4200593 B2 JP 4200593B2 JP 17566599 A JP17566599 A JP 17566599A JP 17566599 A JP17566599 A JP 17566599A JP 4200593 B2 JP4200593 B2 JP 4200593B2
- Authority
- JP
- Japan
- Prior art keywords
- ascorbic acid
- aps
- phosphate
- ion
- sodium salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- HYHGLHONPBPZGJ-YCWPWOODSA-L disodium;[(2r)-2-[(1s)-1,2-dihydroxyethyl]-3-hydroxy-5-oxo-2h-furan-4-yl] phosphate Chemical compound [Na+].[Na+].OC[C@H](O)[C@H]1OC(=O)C(OP(O)([O-])=O)=C1[O-] HYHGLHONPBPZGJ-YCWPWOODSA-L 0.000 title claims description 16
- 238000000034 method Methods 0.000 title description 7
- 239000000243 solution Substances 0.000 claims description 53
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 39
- 239000003960 organic solvent Substances 0.000 claims description 32
- 238000004519 manufacturing process Methods 0.000 claims description 18
- 229910001415 sodium ion Inorganic materials 0.000 claims description 18
- -1 aliphatic alcohols Chemical class 0.000 claims description 14
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 13
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 claims description 13
- 239000007864 aqueous solution Substances 0.000 claims description 12
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- MIJPAVRNWPDMOR-ZAFYKAAXSA-N L-ascorbic acid 2-phosphate Chemical compound OC[C@H](O)[C@H]1OC(=O)C(OP(O)(O)=O)=C1O MIJPAVRNWPDMOR-ZAFYKAAXSA-N 0.000 claims description 5
- 239000013078 crystal Substances 0.000 claims description 5
- 229910019142 PO4 Inorganic materials 0.000 claims description 4
- 150000002576 ketones Chemical class 0.000 claims description 4
- 239000010452 phosphate Substances 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 125000001931 aliphatic group Chemical group 0.000 claims description 3
- 150000004292 cyclic ethers Chemical class 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 229920006395 saturated elastomer Polymers 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- 229910052698 phosphorus Inorganic materials 0.000 claims description 2
- 239000011574 phosphorus Substances 0.000 claims description 2
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 2
- 229940085991 phosphate ion Drugs 0.000 claims 3
- 239000002178 crystalline material Substances 0.000 claims 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 239000007787 solid Substances 0.000 description 15
- 238000001816 cooling Methods 0.000 description 10
- 150000002500 ions Chemical class 0.000 description 10
- 239000012299 nitrogen atmosphere Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 229960005070 ascorbic acid Drugs 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 238000011084 recovery Methods 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 239000002211 L-ascorbic acid Substances 0.000 description 5
- 235000000069 L-ascorbic acid Nutrition 0.000 description 5
- 238000004040 coloring Methods 0.000 description 5
- 239000002537 cosmetic Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 238000002441 X-ray diffraction Methods 0.000 description 3
- 238000000862 absorption spectrum Methods 0.000 description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 150000001342 alkaline earth metals Chemical class 0.000 description 2
- 229920001429 chelating resin Polymers 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000002845 discoloration Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 125000000962 organic group Chemical group 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 230000000865 phosphorylative effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- POXUQBFHDHCZAD-MHTLYPKNSA-N (2r)-2-[(4s)-2,2-dimethyl-1,3-dioxolan-4-yl]-3,4-dihydroxy-2h-furan-5-one Chemical compound O1C(C)(C)OC[C@H]1[C@@H]1C(O)=C(O)C(=O)O1 POXUQBFHDHCZAD-MHTLYPKNSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- POXUQBFHDHCZAD-UHFFFAOYSA-N 2-(2,2-dimethyl-1,3-dioxolan-4-yl)-3,4-dihydroxy-2h-furan-5-one Chemical compound O1C(C)(C)OCC1C1C(O)=C(O)C(=O)O1 POXUQBFHDHCZAD-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 150000000996 L-ascorbic acids Chemical class 0.000 description 1
- ACFGRWJEQJVZTM-LEJBHHMKSA-L Magnesium L-ascorbic acid-2-phosphate Chemical compound [Mg+2].OC[C@H](O)[C@H]1OC(=O)C(OP([O-])([O-])=O)=C1O ACFGRWJEQJVZTM-LEJBHHMKSA-L 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000003788 bath preparation Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 150000003700 vitamin C derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Images
Landscapes
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
【0001】
【発明の属する技術分野】
本発明は、新規な結晶質のL−アスコルビン酸−2−リン酸エステルナトリウム塩(以下「APS」と略記することがある。)およびその製造方法に関する。結晶質APSはL−アスコルビン酸誘導体として有用であり、化粧品、医薬品、食品添加物、その他各種の工業分野に使用される。
【0002】
【従来の技術】
L−アスコルビン酸(ビタミンC)は多様な生理作用、薬理作用を持つことが知られていたが、なかでもメラニン色素沈着防止への効果があることから美白化粧料に用いられてきた。L−アスコルビン酸は、酸素、熱に対して不安定であり、この不安定なL−アスコルビン酸の2位の水酸基をリン酸エステル化することにより、安定化させ、様々な用途に用いられる。特にナトリウム塩、すなわちAPSは水に対して溶解度が高い特徴を持ち、化粧品用途として使われている。
APSの粉末は、従来吸湿性であることにより、長期の保存状態によっては安定性に問題を来す場合があり、加水分解を起こしやすく、元の原料であるビタミンCが生じ、さらに分解する。その結果、この粉末は段々と白色から黄色に変色していくため、化粧品、医薬品、食品添加物等に使用する際に変色、着色の問題が生じる。したがって、保存時の吸湿性改善が望まれている。
APSの製造方法については、L−アスコルビン酸−2−リン酸エステル(以下{AP}と略記することがある。)に関する報告の中に、一部紹介されている。例えば、特開平−2131494号公報に、APSの結晶の製造に関する記述がある。APSを含有する水溶液に、40〜80℃の温度で加熱・還流しながら、メタノールを添加し、さらに、2〜10時間加熱還流した後に、一晩かけて室温まで冷却して、APSの結晶を取得している。この方法では、収率が71〜85%と低い。また、APSを含有する水溶液を40〜80℃という温度で長時間加熱するため、APSの分解がおこり収率が低下することや夾雑するビタミンCが分解して着色する欠点がある。さらに、この方法によると、添加終了後2〜10時間加熱還流を継続することや一晩かけて室温まで冷却するなど生産性が低いという欠点がある。特開平10−17580号公報に、有機溶媒中に非晶質APSを懸濁させ、加熱することにより結晶質APSを製造する方法の記述がある。この方法についても40〜120℃という温度が必要であり、工業的には加温設備と還流設備の設置が必要となり、繁雑となる。さらに、この方法では固体状の非晶質APSを事前に取得する必要があり、非晶質APSは晶析湿体を分離する際の濾過性が悪く、工業的にも効率的な方法とはいえない。
【0003】
【発明が解決しようとする課題】
このように、これまでの吸湿性を改善できる結晶質APSを製造する方法は、簡便性、収率、着色等の面で充分とは言い難い。
【0004】
【課題を解決するための手段】
本発明者は、前記欠点を改善するために鋭意検討した結果、室温近辺で、簡便且つ短時間に、変色、着色の少なく、工業的に生産が容易な吸湿性を改善した新規な結晶質APSが得られることを見いだし、本発明を完成するに至った。
すなわち、本発明は、次の事項に関する。
(1)L−アスコルビン酸−2−リン酸エステルイオンに対するナトリウムイオンがモル比で3未満の水溶液から有機溶媒を貧溶媒として晶析することを特徴とする結晶質L−アスコルビン酸−2−リン酸エステルナトリウム塩の製造方法。
(2)炭素数4以下の低級脂肪族アルコール、炭素数4以下の脂肪族飽和ケトンおよび炭素数4〜6の環状エーテルから選ばれる1種または2種以上の有機溶媒を、L−アスコルビン酸−2−リン酸エステルイオンに対するナトリウムイオンがモル比で3未満になるよう調整されたL−アスコルビン酸−2−リン酸エステルナトリウム塩を含有する水溶液に添加、あるいはL−アスコルビン酸−2−リン酸エステルイオンに対するナトリウムイオンがモル比で3未満になるよう調整されたL−アスコルビン酸−2−リン酸エステルナトリウム塩を含有する水溶液を有機溶媒中に添加し、かかる添加を0〜40℃の温度範囲で、有機溶媒の溶液中濃度が30〜90%(V/V)になるように、0.5〜10時間かけて滴下することを特徴とする結晶質L−アスコルビン酸−2−リン酸エステルナトリウム塩の製造方法。
(3)L−アスコルビン酸−2−リン酸エステルイオンに対するナトリウムイオンがモル比で2.70〜2.99である(1)または(2)に記載の製造方法。
【0005】
(4)L−アスコルビン酸−2−リン酸エステルナトリウム塩の濃度が溶液中で1〜15(wt/V)である(1)〜(3)のいずれかに記載の製造方法。
(5)有機溶媒が、メタノールおよび/またはアセトンである(1)〜(4)のいずれかに記載の製造方法。
(6)CuKα線を用いる粉末X線回折で、面間隔d( )および相対強度[()内に%で表わす。]の解析パターンが実験誤差の範囲内で10.35(61)、8.45(100)、7.09(27)、6.43(8)、5.76(9)、5.16(89)、4.96(30)、4.57(10)、4.37(28)、4.20(47)、4.13(18)4.01(14)、3.59(47)、3.47(39)、3.37(10)、3.29(17)、3.11(57)、3.07(49)、3.03(30)、2.99(25)、2.95(21)、2.90(11)、2.81(17)、2.74(23)、2.67(40)、2.57(60)、2.43(19)、2.35(34)、2.28(13)、2.23(10)、2.06(19)、1.94(12)、1.85(10)、1.76(12)である結晶質L−アスコルビン酸−2−リン酸エステルナトリウム塩。
【0006】
【発明の実施の形態】
以下に本発明を具体的に説明する。
【0007】
本発明に係る新規な結晶質APSは次の物理化学的性質を示す。
(1)X線回折スペクトル;CuKα線、40kV、40mAの条件で測定して得られたX線回折結果を 面間隔d( )および相対強度[()内に%で表す。]は次のとおりである。ただし、X線回折結果は測定条件によっては、通常許容される範囲内で変更する。
10.345(61)、8.450(100)、7.087(27)6.430(8)、5.764(9)、5.157(89)、4.957(30)、4.572(10)、4.367(28)、4.203(47)、4.134(18)4.005(14)、3.593(47)、3.466(39)、3.368(10)、3.288(17)、3.114(57)、3.074(49)、3.025(30)、2.988(25)、2.947(21)、2.899(11)、2.812(17)、2.743(23)、2.673(40)、2.573(60)、2.434(19)、2.352(34)、2.278(13)、2.230(10)、2.064(19)、1.940(12)、1.847(10)、1.762(12)。
(2)赤外吸収スペクトル;KBr錠剤法で測定した赤外吸収スペクトルを第1図に示す。
(3)溶解性は、水に可溶(25℃における溶解度は38%(wt/V)であり、有機溶媒に不溶(アルコール類、ケトン類、クロロホルム等)である。
(4)吸湿性は、第2図に非晶質APSとの吸湿による重量増加率の比較を示す。
【0008】
本発明の結晶質APSの製造方法によると、APイオンに対するナトリウムイオンがモル比で3未満になるよう調整されたAPSを含有する溶液を使用する。
APイオンに対するナトリウムイオンがモル比で3を越えるよう調整されたAPSを含有する溶液に有機溶媒を滴下した場合、0〜40℃の温度条件であっても、析出したAPSは、飴状で部分的に寒天状になり分離が困難になる。APイオンに対するナトリウムイオンがモル比で3を越えるよう調整されたAPSを含有する溶液を有機溶媒に滴下した場合、非結晶のAPSかあるいは特開平2-131494号公報に記述された結晶質APSが生成するが、晶析後分離による濾過性が悪くなり、分離が困難になり、固液分離不良による純度の低下を招く。
【0009】
しかしながら、APイオンに対するナトリウムイオンがモル比で3未満になるよう調整されたAPSを含有する溶液を使用すると、APSを含有する溶液中に有機溶媒を添加好ましくは滴下、あるいはAPSを含有する溶液を有機溶媒中に添加好ましくは滴下する場合のいずれも結晶質のAPSが取得でき、晶析後分離の濾過性も非常に良い。
【0010】
このように、室温近辺、特に0〜40℃の温度条件で、APイオンに対するナトリウムイオンがモル比で3未満になるよう調整されたAPSを含有する溶液で晶析を行い、結晶質APSを取得することにより、短時間に効率よく、品質の良い結晶質のAPSを製造することができる。
本発明で用いられるAPSを含有する溶液は、APを含有している溶液であればよいが、水溶液が好ましい。AP溶液、APのアルカリ金属塩溶液もしくはアルカリ土類金属塩溶液などから調製できる。例えば、アスコルビン酸を直接ホスホリル化して得られたAP含有溶液(特公昭43−9219号公報、特公昭45-23746号公報、特開平6-345786公報等)が挙げられる。また、5,6−O−イソプロピリデン−L−アスコルビン酸をホスホリル化して得られたAP含有溶液(特公昭43−9219号公報、特公昭45−4497号公報、特公昭45−30328号公報、特公昭59−4438号公報等)も好適に利用できる。更に、L−アスコルビン酸とリン酸供与体とから酵素あるいは微生物の作用により生成したAP含有溶液(特開平2−42996号公報等)も利用できる。金属塩としてはカリウム塩、ナトリウム塩、アルカリ土類金属塩としてはマグネシウム塩、カルシウム塩が挙げられる。
【0011】
APが塩の形である場合、あるいはAP含有溶液がアルカリ金属、アルカリ土類金属を含有する場合は、その水溶液を適当なイオン交換樹脂で処理して脱カチオンすることが望ましい。APをイオン交換樹脂に吸着させ、0.1〜2Nの希塩酸で溶出した後、水酸化ナトリウムでナトリウム量の調整が行われる。
水酸化ナトリウムによるナトリウム量調整は、通常10〜48%の水酸化ナトリウム水溶液で行われる。調整するナトリウムの範囲はAPイオンに対するナトリウムイオンがモル比で3未満であるが、回収率の観点から、その範囲が2.70〜2.99であることが特に好ましい。
ナトリウム調整後の溶液中のAPSの濃度は1〜15%(wt/V)、好ましくは5〜10%(wt/V)であり、必要に応じて水で希釈し、あるいは加熱、減圧、逆浸透膜等によって濃縮される。
【0012】
次いで撹拌下、下記に示す有機溶媒を、添加終了後の溶液中の有機溶媒濃度が30〜90%(V/V)の範囲内で用い、APSを含有する溶液を有機溶媒中に添加好ましくは滴下する。この時に用いられる有機溶媒の量は、少なすぎるとAPSの回収率が低下する。一方、多すぎてもAPSの回収率にはほとんど変化ない。したがって、用いる有機溶媒の種類によって多少異なるが、50〜80%(V/V)の範囲が特に好ましい。
【0013】
本発明で用いられる有機溶媒は、メタノール、エタノール、イソプロピルアルコール等の炭素数4以下の低級脂肪族アルコール類、アセトン、メチルエチルケトン等の炭素数4以下の脂肪族飽和ケトン類、およびテトラヒドロフラン、1,4−ジオキサン等の炭素数4〜6の環状エーテル類が挙げられる。これらの溶媒は単独でも、混合しても用いることができる。これらの有機溶媒は、APSを固体として単離した後、水−有機溶媒系の母液から蒸留などの操作によって回収されるため、共沸点をもたずに低沸点で安価な溶媒が好ましい。したがって、メタノール、アセトンまたはその混合溶媒が特に好ましい。
【0014】
APSを含有する溶液を有機溶媒中に添加する時の温度は、室温近辺、特に0〜40℃で行わうことが適当である。APSを含有する溶液と有機溶媒を混合すると、混ざる時に希釈熱を発するため、予め有機溶媒あるいはAPSを含有する溶液を10〜20℃に冷却しておき、また、添加するAPSを含有する溶液あるいは有機溶媒も予め10〜20℃に冷却しておくことが好ましい。添加中の温度が、40℃以上になると、APSの分解や夾雑するVCの分解がおこり、着色するため好ましくない。また、0℃以下の温度ではAPSの回収率や着色に関する問題はないが、冷凍機などの冷却設備の能力を大きくしなければならないため経済的に不利である。添加中も冷却を継続し、10〜30℃に保ちながら添加を行うことが、特に好ましい。
【0015】
APSを含有する溶液を添加するのに要する時間は、0.5〜10時間である。滴下時間が速すぎると、析出したAPSの粒子径が細かくなり、遠心分離機で分離取得する際に目漏れをおこし回収率が低くなる。滴下時間が遅い場合は、回収率や着色に問題はないが、無意味にプラントを占有するため経済的に不利になる。したがって、1〜6時間で添加することが特に好ましい。
【0016】
有機溶媒中にAPSを含有する溶液を滴下した後、0〜40℃の温度で0.25〜1時間熟成させ、遠心分離機等の装置を用いて、APSの固体を単離し、前記有機溶媒で充分洗浄した後、真空乾燥等の処理によって、白色粉末状の結晶質APSが、高純度かつ高収率で得られる。
【0017】
本発明の結晶質APS製造方法においては、有機溶媒中に予め本発明に係る結晶質APSを種晶として添加しておき、この有機溶媒にAPイオンに対するナトリウムイオンがモル比で3未満のAPSを含有する水溶液を添加することにより本発明に係る結晶質APSを製造することができる。
【0018】
本発明の製造方法によって得られる結晶質APSは、吸湿性が少なく、安定性に優れており、例えば医薬品(例、口腔用薬剤、点眼剤、浴用剤等)、化粧品(例、化粧水、乳液、クリーム、パック等)、食品(例、パン等)などとして用いられる。
【0019】
【実施例】
次に実施例によって、本発明を更に詳しく説明するが、本発明はこれら実施例に限定されるものではない。
【0020】
実施例1
窒素雰囲気下、純水1210mL、ピリジン303g及び5,6−イソプロピリデン−L−アスコルビン酸150gを混合溶解し、0〜10℃に冷却後、50%水酸化カリウム水溶液を加えて、pHを約13に調整した。この溶液に、オキシ塩化リン150gと50%水酸化カリウム水溶液とを滴下しながら、pH13、0〜10℃の温度を保って反応を行った。滴下終了後、ピリジンを減圧下、留去し、35%塩酸を加えてpHを4に調整した。
このpH調整液に純水6500mLを加えて希釈した後、中塩基性陰イオン交換樹脂(アンバーライトIRA−68 オルガノ製)2000mLを詰めたカラムに通した。次いで、0.05N−塩酸23.5Lで展開した。更に、0.2N−塩酸11Lで展開し、APのみを含有する分画区分を得た。
この分画区分の溶液に48%水酸化ナトリウム水溶液を加え、2−APイオンのモル量に対するナトリウムイオンのモル量の比が2.85になるように調整した。減圧下、APSの濃度が9%(wt/V)になるまで濃縮操作を加え、APSを含有する溶液を得た。
窒素雰囲気下、95%メタノール750mLを400rpm の速度で撹拌し、10〜15℃に冷却した。予め10〜15℃に冷却しておいたAPSを含有する溶液250mLを、液の温度が10〜25℃の範囲になるように冷却を継続しながら、4時間かけて滴下した。滴下終了後、さらに1時間撹拌を継続し、熟成させた。
【0021】
遠心分離機を用いて、析出したAPSの固体を濾取し、その固体を95%メタノール100mLで充分に洗浄した。
真空下、40℃で乾燥し、結晶質APSを20.0g(収率89%)得た。
【0022】
実施例2
実施例1と同様な方法でAPSを含有する溶液を調製した。
窒素雰囲気下、98%アセトン500mLを400rpm の速度で撹拌し、10〜15℃に冷却した。予め10〜15℃に冷却しておいたAPSを含有する出発溶液250mLを、液の温度が10〜25℃の範囲になるように冷却を継続しながら、4時間かけて滴下した。滴下終了後、さらに0.5時間撹拌を継続し熟成させた。
遠心分離機を用いて、析出したAPSの固体を濾取し、その固体を98%アセトン80mLで充分に洗浄した。
真空下、40℃で乾燥し、結晶質APSを20.5g(収率91%)得た。
【0023】
実施例3
実施例1と同様な方法でAPSを含有する溶液を調製した。
窒素雰囲気下、98%テトラヒドロフラン750mLを400rpmの速度で撹拌し、10〜15℃に冷却した。予め10〜15℃に冷却しておいたAPSを含有する出発溶液250mLを、液の温度が10〜25℃の範囲になるように冷却を継続しながら、2時間かけて滴下した。滴下終了後、更に1時間撹拌を継続し熟成させた。
遠心分離機を用いて、析出したAPSの固体を濾取し、その固体を98%テトラヒドロフラン120mLで充分に洗浄した。
真空下、40℃で乾燥し、結晶質APSを19.6g(収率87%)得た。
【0024】
実施例4
実施例1と同様な方法でAPSを含有する溶液を調製したが、この時のAPイオンのモル量に対するナトリウムイオンのモル比が2.55に調整した。
窒素雰囲気下、95%メタノール750mLを400rpmの速度で撹拌し、10〜15℃に冷却した。予め10〜15℃に冷却しておいたAPSを含有する出発溶液250mLを、液の温度が10〜25℃の範囲になるように冷却を継続しながら、6時間かけて滴下した。滴下終了後、さらに0.5時間撹拌を継続し熟成させた。
遠心分離機を用いて、析出したAPSの固体を濾取し、その固体を95%メタノール100mLで充分に洗浄した。
真空下、40℃で乾燥し、結晶質APSを15.8g(収率70%)得た。
【0025】
実施例5
L−アスコルビン酸−2−リン酸エステルマグネシウム塩32gを純水368gに溶解した。この溶液を強酸性陽イオン交換樹脂(アンバーライトIR−120B オルガノ製)2000mLを詰めたカラムに通した。更に純水1200 を通してAPのみを含有する溶液1600mLを得た。この溶液に含まれるマグネシウムイオンは3ppm以下であった。
この溶液に48%水酸化ナトリウム水溶液を加え、APイオンに対するナトリウムイオンのモル比が2.85になるように調整した。減圧下、APSの濃度が9%(wt/V)になるまで濃縮操作を加え、出発溶液を得た。
窒素雰囲気下、95%メタノール750mLを400rpmの速度で撹拌し、10〜15℃に冷却した。予め10〜15℃に冷却しておいたAPSを含有する出発溶液250mLを、液の温度が10〜25℃の範囲になるように冷却を継続しながら、2時間かけて滴下した。滴下終了後、さらに0.25時間撹拌を継続し、熟成させた。
遠心分離機を用いて、析出したAPSの固体を濾取し、その固体を95%メタノール100mLで充分に洗浄した。
真空下、40℃で乾燥し、結晶質APSを20.7g(収率92%)得た。
【0026】
実施例6
実施例1と同様な方法でAPSを含有する出発溶液を調整した。
窒素雰囲気下、APSを含有する出発溶液250mLを300rpmの速度で撹拌し、10〜15℃に冷却した。予め10〜15℃に冷却しておいた95%メタノール750mLを、液の温度が10〜25℃の範囲になるように冷却を継続しながら、4時間かけて滴下した。滴下終了後、更に0.5時間撹拌を継続し、熟成させた。
遠心分離機を用いて、析出したAPSの固体を濾取し、その固体を95%メタノール100mLで充分に洗浄した。
真空下、40℃で乾燥し、結晶質APSを20.3g(収率90%)得た。
【0027】
【発明の効果】
本発明の製造方法により、簡便且つ高収率に結晶質のL−アスコルビン酸−2−リン酸エステルナトリウム塩が提供される。また、本発明により、吸湿性が少なく安定性の優れた新規な結晶質L−アスコルビン酸−2−リン酸エステルナトリウム塩が提供される。
【0028】
【図面の簡単な説明】
【図1】本発明で得られた結晶質L−アスコルビン酸−2−リン酸エステルナトリウム塩の赤外線吸収スペクトルである。
【図2】結晶質L−アスコルビン酸−2−リン酸エステルナトリウム塩と非晶質L−アスコルビン酸−2−リン酸エステルナトリウム塩の吸湿(条件:相対湿度75±5%、温度25℃)による重量増加率の比較データである。縦軸は元の重量と比較したときの増加率を示し、横軸は時間を示す。
【0029】
【符号の説明】
1 結晶質L−アスコルビン酸−2−リン酸エステルナトリウム塩の吸湿増加率曲線
2 非晶質L−アスコルビン酸−2−リン酸エステルナトリウム塩の吸湿増加率曲線[0001]
BACKGROUND OF THE INVENTION
The present invention relates to a novel crystalline L-ascorbic acid-2-phosphate sodium salt (hereinafter sometimes abbreviated as “APS”) and a method for producing the same. Crystalline APS is useful as an L-ascorbic acid derivative and is used in cosmetics, pharmaceuticals, food additives, and other various industrial fields.
[0002]
[Prior art]
L-ascorbic acid (vitamin C) has been known to have various physiological actions and pharmacological actions, and has been used in whitening cosmetics because it has an effect of preventing melanin pigmentation. L-ascorbic acid is unstable with respect to oxygen and heat. The L-ascorbic acid is stabilized by phosphoric esterification at the 2-position hydroxyl group of the unstable L-ascorbic acid and used for various applications. In particular, sodium salt, that is, APS, has a feature of high solubility in water and is used for cosmetics.
Since APS powder is hygroscopic in the past, it may cause stability problems depending on the long-term storage state, is likely to be hydrolyzed, and vitamin C, the original raw material, is generated and further decomposed. As a result, this powder gradually changes from white to yellow, which causes problems of discoloration and coloring when used in cosmetics, pharmaceuticals, food additives and the like. Therefore, improvement in hygroscopicity during storage is desired.
About the manufacturing method of APS, a part is introduced in the report regarding L-ascorbic acid-2-phosphate ester (it may abbreviate as {AP} hereafter). For example, Japanese Patent Laid-Open No. 2131494 has a description relating to the manufacture of APS crystals. Methanol was added to the aqueous solution containing APS while heating and refluxing at a temperature of 40 to 80 ° C., and the mixture was further heated to reflux for 2 to 10 hours, and then cooled to room temperature overnight to obtain APS crystals. Have acquired. In this method, the yield is as low as 71 to 85%. In addition, since an aqueous solution containing APS is heated at a temperature of 40 to 80 ° C. for a long time, there is a defect that APS is decomposed to reduce the yield and contaminated vitamin C is decomposed and colored. Furthermore, according to this method, there is a disadvantage that productivity is low, such as continuing heating and refluxing for 2 to 10 hours after completion of addition or cooling to room temperature overnight. Japanese Patent Laid-Open No. 10-17580 describes a method for producing crystalline APS by suspending amorphous APS in an organic solvent and heating. This method also requires a temperature of 40 to 120 ° C., and industrially requires installation of heating equipment and reflux equipment, which is complicated. Furthermore, in this method, it is necessary to obtain solid amorphous APS in advance, and amorphous APS has poor filterability when separating crystallization wet bodies, and is an industrially efficient method. I can't say that.
[0003]
[Problems to be solved by the invention]
Thus, the conventional method for producing crystalline APS capable of improving hygroscopicity is not sufficient in terms of simplicity, yield, coloring and the like.
[0004]
[Means for Solving the Problems]
As a result of intensive studies to improve the above-mentioned drawbacks, the present inventors have found that a novel crystalline APS that has improved hygroscopicity that is easy to produce industrially, with little discoloration and coloring, near room temperature, in a simple and short time. Has been found, and the present invention has been completed.
That is, the present invention relates to the following matters.
(1) Crystalline L-ascorbic acid-2-phosphorus, characterized by crystallizing an organic solvent as a poor solvent from an aqueous solution having a molar ratio of sodium ions to L-ascorbic acid-2-phosphate ions of less than 3 Method for producing acid ester sodium salt.
(2) One or more organic solvents selected from lower aliphatic alcohols having 4 or less carbon atoms, aliphatic saturated ketones having 4 or less carbon atoms, and cyclic ethers having 4 to 6 carbon atoms are used as L-ascorbic acid- Addition to an aqueous solution containing L-ascorbic acid-2-phosphate sodium salt adjusted so that the sodium ion to 2-phosphate ester ion is less than 3 in molar ratio, or L-ascorbic acid-2-phosphate An aqueous solution containing L-ascorbic acid-2-phosphate sodium salt adjusted to have a sodium ion to ester ion molar ratio of less than 3 is added to an organic solvent, and the addition is performed at a temperature of 0 to 40 ° C. In the range, it is dripped over 0.5 to 10 hours so that the density | concentration in the solution of an organic solvent may be 30 to 90% (V / V) Method for producing a crystalline L- ascorbic acid 2-phosphate ester sodium salt.
(3) The manufacturing method as described in (1) or (2) whose sodium ion with respect to L-ascorbic acid-2-phosphate ester ion is 2.70-2.99 by molar ratio.
[0005]
(4) The production method according to any one of (1) to (3), wherein the concentration of L-ascorbic acid-2-phosphate sodium salt is 1 to 15 (wt / V) in the solution.
(5) The production method according to any one of (1) to (4), wherein the organic solvent is methanol and / or acetone.
(6) Powder X-ray diffraction using CuKα rays, with interplanar spacing d () and relative intensity [expressed in% in (). ] Within the range of experimental error 10.35 (61), 8.45 (100), 7.09 (27), 6.43 (8), 5.76 (9), 5.16 ( 89), 4.96 (30), 4.57 (10), 4.37 (28), 4.20 (47), 4.13 (18) 4.01 (14), 3.59 (47) 3.47 (39), 3.37 (10), 3.29 (17), 3.11 (57), 3.07 (49), 3.03 (30), 2.99 (25), 2.95 (21), 2.90 (11), 2.81 (17), 2.74 (23), 2.67 (40), 2.57 (60), 2.43 (19), 2 .35 (34), 2.28 (13), 2.23 (10), 2.06 (19), 1.94 (12), 1.85 (10), 1.76 (12) crystals Quality L-Asco Bin 2-phosphate ester sodium salt.
[0006]
DETAILED DESCRIPTION OF THE INVENTION
The present invention will be specifically described below.
[0007]
The novel crystalline APS according to the present invention exhibits the following physicochemical properties.
(1) X-ray diffraction spectrum: X-ray diffraction results obtained by measurement under the conditions of CuKα ray, 40 kV, and 40 mA are expressed in terms of interplanar spacing d () and relative intensity [(). ] Is as follows. However, the X-ray diffraction result is changed within a generally allowable range depending on measurement conditions.
10.345 (61), 8.450 (100), 7.087 (27) 6.430 (8), 5.764 (9), 5.157 (89), 4.957 (30), 4. 572 (10), 4.367 (28), 4.203 (47), 4.134 (18) 4.005 (14), 3.593 (47), 3.466 (39), 3.368 ( 10), 3.288 (17), 3.114 (57), 3.074 (49), 3.025 (30), 2.988 (25), 2.947 (21), 2.899 (11) ), 2.812 (17), 2.743 (23), 2.673 (40), 2.573 (60), 2.434 (19), 2.352 (34), 2.278 (13) 2.230 (10), 2.064 (19), 1.940 (12), 1.847 (10), 1.762 12).
(2) Infrared absorption spectrum: FIG. 1 shows an infrared absorption spectrum measured by the KBr tablet method.
(3) Solubility is soluble in water (solubility at 25 ° C. is 38% (wt / V) and insoluble in organic solvents (alcohols, ketones, chloroform, etc.).
(4) Hygroscopicity shows a comparison of the rate of weight increase due to moisture absorption with amorphous APS in FIG.
[0008]
According to the method for producing crystalline APS of the present invention, a solution containing APS adjusted so that sodium ion to AP ion is less than 3 in molar ratio is used.
When an organic solvent is dropped into a solution containing APS adjusted so that the sodium ion to AP ion exceeds 3 in molar ratio, the deposited APS is partially in a bowl shape even under a temperature condition of 0 to 40 ° C. Becomes agar-like and difficult to separate. When a solution containing APS adjusted so that the sodium ion to AP ion exceeds 3 in molar ratio is dropped into an organic solvent, either amorphous APS or crystalline APS described in JP-A-2-131494 is produced. Although produced, the filterability by separation after crystallization is deteriorated, separation becomes difficult, and the purity is lowered due to poor solid-liquid separation.
[0009]
However, when a solution containing APS adjusted so that the sodium ion to AP ion is less than 3 in molar ratio is used, an organic solvent is preferably added dropwise to the solution containing APS, or a solution containing APS is added. Crystalline APS can be obtained in any case where it is preferably added dropwise to an organic solvent, and the filterability of separation after crystallization is very good.
[0010]
In this way, crystallization is performed with a solution containing APS adjusted so that the sodium ion to AP ion is less than 3 in a molar ratio near room temperature, particularly 0 to 40 ° C., thereby obtaining crystalline APS. By doing so, it is possible to produce a crystalline APS with good quality and efficiency in a short time.
The solution containing APS used in the present invention may be a solution containing AP, but an aqueous solution is preferable. It can be prepared from an AP solution, an alkali metal salt solution of AP, or an alkaline earth metal salt solution. Examples thereof include AP-containing solutions obtained by directly phosphorylating ascorbic acid (Japanese Patent Publication No. 43-9219, Japanese Patent Publication No. 45-23746, Japanese Patent Laid-Open No. 6-345786, etc.). Further, AP-containing solutions obtained by phosphorylating 5,6-O-isopropylidene-L-ascorbic acid (Japanese Patent Publication No. 43-9219, Japanese Patent Publication No. 45-4497, Japanese Patent Publication No. 45-30328), Japanese Examined Patent Publication No. 59-4438 can also be suitably used. Furthermore, an AP-containing solution (Japanese Patent Laid-Open No. 2-42996, etc.) produced from L-ascorbic acid and a phosphate donor by the action of an enzyme or a microorganism can also be used. Examples of the metal salt include potassium salt and sodium salt, and examples of the alkaline earth metal salt include magnesium salt and calcium salt.
[0011]
When AP is in the form of a salt, or when the AP-containing solution contains an alkali metal or alkaline earth metal, it is desirable to decationize the aqueous solution by treating it with an appropriate ion exchange resin. AP is adsorbed on an ion exchange resin and eluted with 0.1 to 2N dilute hydrochloric acid, and then the amount of sodium is adjusted with sodium hydroxide.
Adjustment of the amount of sodium with sodium hydroxide is usually performed with a 10 to 48% sodium hydroxide aqueous solution. The range of sodium to be adjusted is that sodium ions with respect to AP ions are less than 3 in terms of molar ratio, but from the viewpoint of recovery, the range is particularly preferably 2.70 to 2.99.
The concentration of APS in the solution after sodium adjustment is 1 to 15% (wt / V), preferably 5 to 10% (wt / V). If necessary, dilute with water, or heat, decompress, reverse It is concentrated by an osmotic membrane or the like.
[0012]
Then, under stirring, the organic solvent shown below is used within the range of the organic solvent concentration in the solution after the addition is 30 to 90% (V / V), and the solution containing APS is preferably added to the organic solvent. Dripping. If the amount of the organic solvent used at this time is too small, the recovery rate of APS is lowered. On the other hand, even if it is too much, there is almost no change in the recovery rate of APS. Therefore, the range of 50 to 80% (V / V) is particularly preferable, although it varies somewhat depending on the type of organic solvent used.
[0013]
The organic solvent used in the present invention includes lower aliphatic alcohols having 4 or less carbon atoms such as methanol, ethanol and isopropyl alcohol, aliphatic saturated ketones having 4 or less carbon atoms such as acetone and methyl ethyl ketone, and tetrahydrofuran, 1, 4 -C4-C6 cyclic ethers, such as a dioxane, are mentioned. These solvents can be used alone or in combination. Since these organic solvents are recovered from the water-organic solvent-based mother liquor by an operation such as distillation after isolating APS as a solid, low-boiling and inexpensive solvents having no azeotropic point are preferred. Therefore, methanol, acetone or a mixed solvent thereof is particularly preferable.
[0014]
The temperature at which the solution containing APS is added to the organic solvent is suitably around room temperature, particularly 0 to 40 ° C. When a solution containing APS and an organic solvent are mixed, a heat of dilution is generated when they are mixed. Therefore, the solution containing the organic solvent or APS is cooled to 10 to 20 ° C. in advance, and the solution containing APS to be added or It is preferable to cool the organic solvent to 10 to 20 ° C. in advance. If the temperature during the addition is 40 ° C. or higher, APS decomposition or contaminating VC decomposition occurs, resulting in coloration. Moreover, although there is no problem regarding the recovery rate or coloring of APS at a temperature of 0 ° C. or lower, it is economically disadvantageous because the capacity of a cooling facility such as a refrigerator must be increased. It is particularly preferable to continue cooling during the addition and to keep the addition at 10 to 30 ° C.
[0015]
The time required to add the solution containing APS is 0.5 to 10 hours. If the dripping time is too fast, the particle size of the precipitated APS will be fine, causing leakage during separation and acquisition with a centrifuge, resulting in a low recovery rate. When the dropping time is slow, there is no problem in the recovery rate and coloring, but it is economically disadvantageous because it occupies the plant meaninglessly. Therefore, it is particularly preferable to add in 1 to 6 hours.
[0016]
After dropping a solution containing APS in an organic solvent, aging is performed at a temperature of 0 to 40 ° C. for 0.25 to 1 hour, and using a device such as a centrifuge, the solid of APS is isolated, and the organic solvent After sufficiently washing with, a white powdery crystalline APS is obtained with high purity and high yield by treatment such as vacuum drying.
[0017]
In the crystalline APS production method of the present invention, the crystalline APS according to the present invention is added as a seed crystal in advance to an organic solvent, and an APS having a sodium ion to AP ion molar ratio of less than 3 is added to the organic solvent. The crystalline APS according to the present invention can be produced by adding the aqueous solution contained therein.
[0018]
The crystalline APS obtained by the production method of the present invention has low hygroscopicity and excellent stability. For example, pharmaceuticals (eg, oral medicine, eye drops, bath preparations, etc.), cosmetics (eg, lotion, emulsion) , Cream, pack, etc.), food (eg, bread, etc.) and the like.
[0019]
【Example】
EXAMPLES Next, although an Example demonstrates this invention in more detail, this invention is not limited to these Examples.
[0020]
Example 1
Under a nitrogen atmosphere, 1210 mL of pure water, 303 g of pyridine, and 150 g of 5,6-isopropylidene-L-ascorbic acid are mixed and dissolved. After cooling to 0 to 10 ° C., a 50% aqueous potassium hydroxide solution is added to adjust the pH to about 13 Adjusted. To this solution, 150 g of phosphorus oxychloride and a 50% aqueous potassium hydroxide solution were added dropwise, and the reaction was carried out while maintaining a pH of 13 to 0 to 10 ° C. After completion of the dropwise addition, pyridine was distilled off under reduced pressure, and 35% hydrochloric acid was added to adjust the pH to 4.
The pH adjustment solution was diluted by adding 6500 mL of pure water, and then passed through a column packed with 2000 mL of a medium basic anion exchange resin (Amberlite IRA-68 Organo). Subsequently, it developed with 23.5 L of 0.05 N hydrochloric acid. Furthermore, it developed by 0.2L-hydrochloric acid 11L, and the fraction division containing only AP was obtained.
A 48% aqueous sodium hydroxide solution was added to the solution in this fractionation section, and the ratio of the molar amount of sodium ions to the molar amount of 2-AP ions was adjusted to 2.85. Under reduced pressure, a concentration operation was performed until the concentration of APS was 9% (wt / V) to obtain a solution containing APS.
Under a nitrogen atmosphere, 750 mL of 95% methanol was stirred at a speed of 400 rpm and cooled to 10 to 15 ° C. 250 mL of a solution containing APS that had been cooled to 10 to 15 ° C. in advance was added dropwise over 4 hours while continuing cooling so that the temperature of the solution was in the range of 10 to 25 ° C. After completion of the dropwise addition, the mixture was further stirred for 1 hour and aged.
[0021]
Using a centrifuge, the precipitated APS solid was collected by filtration, and the solid was thoroughly washed with 100 mL of 95% methanol.
It was dried at 40 ° C. under vacuum to obtain 20.0 g (yield 89%) of crystalline APS.
[0022]
Example 2
A solution containing APS was prepared in the same manner as in Example 1.
In a nitrogen atmosphere, 500 mL of 98% acetone was stirred at a speed of 400 rpm and cooled to 10 to 15 ° C. 250 mL of a starting solution containing APS that had been cooled to 10 to 15 ° C. in advance was added dropwise over 4 hours while continuing cooling so that the temperature of the solution was in the range of 10 to 25 ° C. After completion of the dropwise addition, the mixture was further aged by continuing stirring for 0.5 hour.
The precipitated APS solid was collected by filtration using a centrifuge, and the solid was thoroughly washed with 80 mL of 98% acetone.
It was dried at 40 ° C. under vacuum to obtain 20.5 g (yield 91%) of crystalline APS.
[0023]
Example 3
A solution containing APS was prepared in the same manner as in Example 1.
Under a nitrogen atmosphere, 750 mL of 98% tetrahydrofuran was stirred at a speed of 400 rpm and cooled to 10 to 15 ° C. 250 mL of a starting solution containing APS that had been cooled to 10 to 15 ° C. in advance was added dropwise over 2 hours while continuing cooling so that the temperature of the solution was in the range of 10 to 25 ° C. After completion of the dropwise addition, the mixture was further aged by continuing stirring for 1 hour.
The precipitated APS solid was collected by filtration using a centrifuge, and the solid was thoroughly washed with 120 mL of 98% tetrahydrofuran.
It dried under vacuum at 40 degreeC and obtained 19.6g (yield 87%) of crystalline APS.
[0024]
Example 4
A solution containing APS was prepared in the same manner as in Example 1, but the molar ratio of sodium ions to the molar amount of AP ions at this time was adjusted to 2.55.
Under a nitrogen atmosphere, 750 mL of 95% methanol was stirred at a speed of 400 rpm and cooled to 10 to 15 ° C. 250 mL of a starting solution containing APS that had been cooled to 10 to 15 ° C. in advance was added dropwise over 6 hours while continuing cooling so that the temperature of the solution was in the range of 10 to 25 ° C. After completion of the dropwise addition, the mixture was further aged by continuing stirring for 0.5 hour.
Using a centrifuge, the precipitated APS solid was collected by filtration, and the solid was thoroughly washed with 100 mL of 95% methanol.
It dried under vacuum at 40 degreeC and obtained 15.8g (yield 70%) of crystalline APS.
[0025]
Example 5
32 g of L-ascorbic acid-2-phosphate magnesium salt was dissolved in 368 g of pure water. This solution was passed through a column packed with 2000 mL of a strongly acidic cation exchange resin (Amberlite IR-120B Organo). Furthermore, 1600 mL of a solution containing only AP was obtained through pure water 1200. The magnesium ion contained in this solution was 3 ppm or less.
A 48% aqueous sodium hydroxide solution was added to this solution, and the molar ratio of sodium ions to AP ions was adjusted to 2.85. Concentration operation was added under reduced pressure until the concentration of APS was 9% (wt / V) to obtain a starting solution.
Under a nitrogen atmosphere, 750 mL of 95% methanol was stirred at a speed of 400 rpm and cooled to 10 to 15 ° C. 250 mL of a starting solution containing APS that had been cooled to 10 to 15 ° C. in advance was added dropwise over 2 hours while continuing cooling so that the temperature of the solution was in the range of 10 to 25 ° C. After completion of the dropwise addition, stirring was continued for 0.25 hours, followed by aging.
Using a centrifuge, the precipitated APS solid was collected by filtration, and the solid was thoroughly washed with 100 mL of 95% methanol.
It was dried at 40 ° C. under vacuum to obtain 20.7 g (yield 92%) of crystalline APS.
[0026]
Example 6
A starting solution containing APS was prepared in the same manner as in Example 1.
Under a nitrogen atmosphere, 250 mL of the starting solution containing APS was stirred at a speed of 300 rpm and cooled to 10 to 15 ° C. 750 mL of 95% methanol that had been cooled to 10 to 15 ° C. in advance was added dropwise over 4 hours while continuing cooling so that the temperature of the liquid was in the range of 10 to 25 ° C. After completion of the dropwise addition, stirring was continued for another 0.5 hours to ripen.
Using a centrifuge, the precipitated APS solid was collected by filtration, and the solid was thoroughly washed with 100 mL of 95% methanol.
It was dried at 40 ° C. under vacuum to obtain 20.3 g (yield 90%) of crystalline APS.
[0027]
【The invention's effect】
The production method of the present invention provides crystalline L-ascorbic acid-2-phosphate sodium salt in a simple and high yield. In addition, the present invention provides a novel crystalline L-ascorbic acid-2-phosphate sodium salt that has low hygroscopicity and excellent stability.
[0028]
[Brief description of the drawings]
FIG. 1 is an infrared absorption spectrum of crystalline L-ascorbic acid-2-phosphate sodium salt obtained in the present invention.
FIG. 2 shows moisture absorption of crystalline L-ascorbic acid-2-phosphate sodium salt and amorphous L-ascorbic acid-2-phosphate sodium salt (conditions: relative humidity 75 ± 5%,
[0029]
[Explanation of symbols]
1 Hygroscopic increase curve of crystalline L-ascorbic acid-2-
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP17566599A JP4200593B2 (en) | 1999-06-22 | 1999-06-22 | Crystalline L-ascorbic acid-2-phosphate sodium salt and process for producing the same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP17566599A JP4200593B2 (en) | 1999-06-22 | 1999-06-22 | Crystalline L-ascorbic acid-2-phosphate sodium salt and process for producing the same |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2001002689A JP2001002689A (en) | 2001-01-09 |
JP4200593B2 true JP4200593B2 (en) | 2008-12-24 |
Family
ID=16000091
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP17566599A Expired - Lifetime JP4200593B2 (en) | 1999-06-22 | 1999-06-22 | Crystalline L-ascorbic acid-2-phosphate sodium salt and process for producing the same |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4200593B2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003000169A1 (en) * | 2001-06-20 | 2003-01-03 | Takeda Chemical Industries, Ltd. | Method of manufacturing tablet |
JP4781855B2 (en) * | 2006-03-08 | 2011-09-28 | 日本メナード化粧品株式会社 | Composite powder and makeup cosmetic containing the composite powder |
JP5402286B2 (en) * | 2008-06-20 | 2014-01-29 | 三菱化学株式会社 | Method for producing phosphorus compound and method for producing allyl compound derivative |
-
1999
- 1999-06-22 JP JP17566599A patent/JP4200593B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
JP2001002689A (en) | 2001-01-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0647649B1 (en) | Novel crystal of monohydrate of heterocyclic bis(phosphonic acid) derivative | |
KR100403256B1 (en) | Crystalline N-Acetyl Neuraminic Acid Derivatives and Processes for Their Preparation | |
JP4200593B2 (en) | Crystalline L-ascorbic acid-2-phosphate sodium salt and process for producing the same | |
US4456753A (en) | Process for the manufacture of highly crystalline sodium cefoperazone | |
SU668608A3 (en) | Method of obtaining gamma-crystalline form of sodium salt of 7-(d-2-formiloxy-2-phenyl-acetamido)-3-(1-methyl-1n-tetrazolil-5-thomethyl)-cephem-4-carboxylic acid | |
NO148887B (en) | PROCEDURE FOR THE PREPARATION OF THE CRYSTALLINIC ANHYDRATED BY SODIUM CEFAMANDOL | |
US4219641A (en) | Process for preparing erythromycin succinate | |
KR20050033525A (en) | New anhydrous crystalline forms of gabapentin | |
JP3750160B2 (en) | Amorphous L-ascorbic acid-2-phosphate ester sodium salt and method for producing the same | |
JP3843490B2 (en) | Method for producing crystalline L-ascorbic acid-2-phosphate sodium salt | |
RU2201419C2 (en) | Method of 6-[3-(2-chlorophenyl)-5-methylisoxazol-4-carbamino]-penicillanic acid sodium salt preparing | |
JP2877366B2 (en) | Method for producing crystalline L-ascorbic acid-2-phosphate sodium salt | |
EP0962461B1 (en) | Crystalline potassium salt of L-ascorbic acid-2-phosphoric acid and method for producting the same | |
EP0007689B1 (en) | Production of sodium cephamandole derivatives | |
EP0107972A1 (en) | A method for optical resolution of alpha-isopropyl-p-chlorophenylacetic acid | |
BG99161A (en) | Method and intermediate product for oxytetracycline purification | |
US6271397B1 (en) | L-ascorbic acid-2-phosphoric acid potassium crystal and method for producing the same | |
US6388098B1 (en) | Process for preparing ascorbic acid-2-monophosphate salt | |
US2906780A (en) | Production of dihydrovitamin k1 | |
JP3378847B2 (en) | Crystals of L-ascorbic acid-2-phosphate sodium salt | |
US3932386A (en) | Sodium 6-(L-aminocyclohexane carboxamido)penicillanic acid | |
EP1072605B1 (en) | Process for producing ascorbic acid-2-phosphoric ester salts | |
US2764612A (en) | Process for preparing salts of glutamic acid | |
US3076004A (en) | Preparation of 2-methyl-3-phytyl-1, 4-naphthohydroquinone ester | |
KR0169534B1 (en) | Process for preparing high density and high crystalline cefoperazone sodium |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060112 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080916 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080929 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 4200593 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111017 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111017 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20141017 Year of fee payment: 6 |
|
EXPY | Cancellation because of completion of term |